Houston, TX (PRWEB) January 15, 2014 <\/p>\n
Located in Houston, Texas, AkesoGenX Corp. has acquired and assumed control of the intellectual property and equipment related to the Kanzius Cancer Treatment technology from Therm Med LLC. The AkesoGenX management team envisions taking John Kanziuss patented Noninvasive Radio Wave Cancer Treatment from pre-FDA research through to human clinical trials, and if results are positive, to commercialization in concert with their strategic partners. The true goal is making this state-of-the-art technology available to treat those afflicted with cancer. <\/p>\n
Origins The reality of current cancer treatment is nothing short of life changing for thousands of patients and their families annuallyno one understood this better than the late John Kanzius. The mission of AkesoGenX Corp. is to provide an alternative noninvasive cancer therapy, which will allow for an effective treatment for cancer patients while reducing side effects associated with traditional chemotherapies and radiation therapies. <\/p>\n
The Team The founding members of AkesoGenX Corp. originate from diverse yet complementary sectors within the medical, science and technology industries and bring years of experience and management expertise. The AkesoGenX management team will provide a solid foundation for the human clinical trials needed for commercialization of this innovative cancer treatment technology. <\/p>\n
Dr Steven Curley Renowned cancer specialist Dr. Curley will continue his role as lead researcher, now at Baylor College of Medicine in the Texas Medical Center. As a co-founder of AkesoGenX Corp., Dr. Curley will be focused on the direction and timing of FDA submission. <\/p>\n
\"I made a promise to my friend John Kanzius in 2008 that I would get his treatment into clinical trials in cancer patients. said Dr. Curley I told Nobel Laureate Professor Richard Smalley in 2005 that I would continue to work combining nano particles with the Kanzius RF field to find an effective, less toxic cancer treatment. I owe an eternal debt of gratitude to the Kanzius Cancer Research Foundation and to people everywhere who have supported the Foundation because this work would not have been possible without your optimism and unflagging support. To the people of Erie, Pennsylvania, Fort Myers, Florida and Sanibel Island, THANK YOU! I am confident this new venture will allow us to move this treatment forward in patients fighting against cancer, and I am excited about the future.\" <\/p>\n
Robert Zavala, CEO Co-founder and CEO of AkesoGenX Corp. Robert will be responsible for developing the strategic direction, mission critical partnerships and overall business operations required to move this innovative-patented technology into human clinical trials. Dr. Curley and Mr. Zavala are honored to lead the efforts toward making this treatment available to those afflicted with cancer. Roberts expertise is within the nano-materials industry and because this cancer treatment is based in part on nano-technology, Roberts experience in that industry will benefit AkesoGenX commercialization efforts. <\/p>\n
Im honored to be a part of the team which has been led by Dr. Curley. Said Robert, AkesoGenX is looking forward to fulfilling the dream of the inventor of the technology, the late John Kanzius. Both Dr. Curley and I are grateful for all of the continued support we have received from the Kanzius Family, the Erie, Pennsylvania and Sanibel Island, Florida communities and the Kanzius Cancer Research Foundation. <\/p>\n
In a statement released today, Maryann, the widow of John Kanzius said, We at Therm Med are very pleased that the technology invented by my late husband, John Kanzius, is in very capable hands with the scientific and business expertise necessary to take this very worthy project to the next level. We wish AkesoGenX the very best. <\/p>\n
AkesoGenX Vision AkesoGenX Corp.s strategic vision is to bring to market significant new nano-diagnostic and nano-therapeutic medical products. The primary goal is to move the Kanzius RF field treatment forward to treat patients with highly lethal and resistant forms of cancer. <\/p>\n
<\/p>\n
Visit link:<\/p>\n
AkesoGenX Corp. Assumes Control of Kanzius Cancer Treatment Technology<\/a><\/p>\n","protected":false},"excerpt":{"rendered":" Houston, TX (PRWEB) January 15, 2014 Located in Houston, Texas, AkesoGenX Corp. Continue reading